Sarepta’s Gene Therapy for Rare Muscle Disease Impresses Wall Street in Early Study

(Bloomberg) -- Sarepta Therapeutics Inc. impressed Wall Street yet again with its updated early-stage data for its Duchenne muscular dystrophy gene therapy. Analysts broadly applauded the results a...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.